

RESEARCH

Open Access



The pancreas-to-muscle signal intensity ratio on T₁-weighted MRI as a predictive biomarker for postoperative pancreatic fistula after distal pancreatectomy: a single-center retrospective study

Masahiro Fukada*, Katsutoshi Murase, Toshiya Higashi, Seito Fujibayashi, Masashi Kuno, Itaru Yasufuku, Yuta Sato, Shigeru Kiyama, Yoshihiro Tanaka, Naoki Okumura, Nobuhisa Matsuhashi and Takao Takahashi

Abstract

Background: Postoperative pancreatic fistula (POPF) is one of the serious complications of pancreatic surgery. When POPF occurs and becomes severe, it causes secondary complications and a longer treatment period. We previously reported a correlation between pancreatic fibrosis and magnetic resonance imaging (MRI) findings, and MRI may have the potential to predict POPF. This study aimed to assess the predictive ability of the pancreas-to-muscle signal intensity ratio on T₁-weighted MRI (SIR on T₁-w MRI) for POPF after distal pancreatectomy (DP).

Methods: This single-institution retrospective study comprised 117 patients who underwent DP. It was conducted between 2010 and 2021 at the Gifu University Hospital. We statistically analyzed pre-, intra-, and postoperative factors to assess the correlation with POPF.

Results: According to the definition and grading of the International Study Group of Pancreatic Fistula (ISGPF), 29 (24.8%) of the 117 patients had POPF grades B and C. In the univariate analysis, POPF was significantly associated with the pancreas-to-muscle SIR on T₁-w MRI, the drainage fluid amylase concentration (D-Amy) levels on postoperative day (POD) 1 and 3, white blood cell count on POD 1 and 3, C-reactive protein level on POD 3, and heart rate on POD 3. In multivariate analysis, only the pancreas-to-muscle SIR on T₁-w MRI (>1.37; odds ratio [OR] 23.25; 95% confidence interval [CI] 3.93–454.03; *p* < 0.01) and D-Amy level on POD 3 (>737 U/l; OR 3.91; 95% CI 1.02–16.36; *p* = 0.046) were identified as independent predictive factors.

Conclusions: The pancreas-to-muscle SIR on T₁-w MRI and postoperative D-Amy levels were able to predict the development of POPF after DP. The pancreas-to-muscle SIR on T₁-w MRI may be a potential objective biomarker reflecting pancreatic status.

Keywords: Signal intensity ratio on T₁-weighted MRI, Postoperative pancreatic fistula, Distal pancreatectomy

Background

Postoperative pancreatic fistula (POPF) is one of the most serious complications of pancreatic surgery for pancreatic disease. POPF causes secondary complications, such as abdominal abscess, delayed gastric

*Correspondence: flyhighvb@yahoo.co.jp

Department of Gastroenterological Surgery, Gifu University Hospital, 1-1 Yanagido, Gifu City, Gifu 501-1194, Japan



emptying, and postoperative bleeding, and may lead to a prolonged hospital stay duration and surgery-related death [1–3]. Although surgical procedures have been standardized and surgical devices developed in pancreatic surgery, the incidence of POPF has been reported to still range from 3 to 50%, even at high-volume centers [4–7]. Furthermore, POPF still occurs at, as high as, 24 to 39% even after distal pancreatectomy (DP) without pancreaticoenteral anastomosis [8–13]. Therefore, POPF is considered to be caused by surgery-related factors and pancreas-related factors.

Pancreatic parenchyma becomes hardened because of fibrosis, and the hardness of the pancreatic parenchyma is known to be associated with POPF [14, 15]. We previously reported a significant correlation between the pathological classification of the pancreatic fibrosis grade and the development of POPF [16, 17]. We also reported using the pancreas-to-muscle signal intensity ratio on T1-weighted MRI (SIR on T1-w MRI) to evaluate pancreatic fibrosis and predict POPF [16, 17].

This study aimed to assess the potential of the pancreas-to-muscle SIR on T₁-w MRI as a predictive factor for POPF after DP.

Methods

Patients

In this single-center retrospective study, we included 134 consecutive patients who underwent DP for pancreatic disease at Gifu University Hospital between January 2010 and December 2021. All procedures were conducted by expert surgeons who had qualified through the board certification system of the Japanese Society of Hepato-Biliary-Pancreatic Surgery (JSHBPS). We excluded 17 patients in total (simultaneous resection of other organs), so 117 patients were included in this study (Fig. 1). We conducted our study in accordance with the World Medical Association Declaration of Helsinki, and the Ethics Committee of Gifu University approved the study (approval number: 2021-026).

Patient characteristics were classified into three categories: pre-, intra-, and postoperative factors (Fig. 2). The six preoperative factors were age, sex, body mass index





Fig. 1 Exclusion criteria



(BMI), pancreatic disease (pancreatic ductal adenocarcinoma (PDAC) or non-PDAC), tumor location, and the pancreas-to-muscle SIR on T₁-w MRI. The six intraoperative factors included operative time, blood loss, surgical procedure (i) open or laparoscopic surgery, (ii) spleen preserving or non-preserving, pancreatic resection procedure (hand-sewn or stapler), pancreas texture (soft or hard), and pancreas thickness measured intraoperatively on resection site. Finally, the five postoperative factors included the amylase concentration levels of drainage fluid (D-Amy), the white blood cell (WBC) count, C-reactive protein (CRP) level, body temperature, and heart rate on postoperative day (POD) 1 and 3. Body temperature was the maximum value and heart rate was the average value on the measurement day.

Perioperative management

In cases of DP for PDAC, regional lymph node dissection with splenectomy following the classification of pancreatic carcinoma of the Japan Pancreas Society [18] and pancreatic resection of the portal vein were performed. In the case of DP for non-PDAC, systematic lymph node dissection was omitted, and pancreatic resection was performed with sufficient margin from

the tumor. Pancreatic resection was performed with a hand-sewn closure or using a linear stapler.

In the hand-sewn closure group, the pancreas was resected after identifying the main pancreatic duct, and the main pancreatic duct was ligated with a 3-0 silk suture. The stump of the remnant pancreas was closed with a vertical mattress suture using 5-0 polypropylene. For the group that underwent pancreatic resection using a linear stapler, the pancreas was resected with a purple or black cartridge using Endo GIA™ Tri-Staple or Signia™ stapling system (Medtronic plc., Dublin, Ireland). The closed jaw was clamped carefully and slowly, taking 5 min, at a fixed speed. The firing was performed at 1 cm per minute by firmly fixing the stapler. After firing, the jaws of the stapler were held shut for 1 min. One 19Fr. Blake silicon drain (Johnson and Johnson Inc. New Brunswick, NJ, USA) was then placed near the stump of the remnant pancreas. The drain was removed on POD 4–5, when the drainage fluid was clear, the postoperative course was stable, and the patient was without abdominal pain, fever, or other symptoms. The D-Amy levels were measured on POD 1, 3, and 5. All patients received prophylactic antibiotics (cefmetazole) only intraoperatively or 2 days postoperatively.

The pancreas-to-muscle signal intensity ratio on T₁-weighted MRI

Previously, we studied the potential value of preoperative MRI in evaluating pancreatic properties [16, 17] and reported that the pancreas-to-muscle SIR on T₁-w MRI significantly correlated with pancreatic fibrosis and that it may be a potential biomarker for predicting POPF for pancreatic surgery. The pancreatic parenchyma's signal intensity (SI) on the portal vein and the paraspinal muscle was measured using fat-suppressed axial T₁-weighted imaging (Fig. 3). The pancreas-to-muscle SIR on T₁-w MRI was calculated using the following equation: [SI of the pancreatic parenchyma]/[SI of the paraspinal muscle].

Definition of POPF

In this study, we included only clinically symptomatic POPF. Therefore, only grades B and C pancreatic fistulas were defined as POPF (grade B, symptomatic fistula requiring therapeutic intervention such as antibiotics and percutaneous drainage; grade C, symptomatic fistula associated with a severe general condition of patients, sepsis, and multiorgan failure requiring aggressive treatment in the intensive care unit and surgical intervention), based on the International Study Group of Pancreatic Fistula (ISGPF) definitions [19]. Diagnosis day of POPF was defined as when intra-abdominal fluid collection with positive cultures was identified by ultrasonography (US) or computed tomography (CT).

Statistical analysis

Continuous variables were expressed as median (range) values, and categorical variables were expressed as frequencies (percentages). For comparisons of variables between the POPF and non-POPF groups, Fisher's exact test was used for categorical variables. A Mann-Whitney

U test was used for continuous variables. The predictive ability for POPF after DP was assessed by calculating the area under the receiver operating characteristic (ROC) curve. Youden's index was used to determine the optimal cutoff value to calculate specificities and sensitivities in the ROC curve analysis. The variables identified as potentially significant by univariate analysis were selected for multivariate analysis with a logistic regression model to identify the independent predictors of POPF after DP. The limit of statistical significance for all analyses was defined as a 2-sided *p*-value of 0.05. All statistical analyses were performed using JMP software (SAS Institute Inc., Cary, NC, USA).

Results

Comparison of clinical outcomes between patients with and without POPF

In total, 117 patients underwent DP for pancreatic disease. Symptomatic POPF occurred in 29 (24.8 %) patients. Patients' clinical outcomes after DP are summarized in Table 1. The median time at which POPF was confirmed was POD 7 (3–25 days). In the patients with POPF, the median time until hospital discharge was 35 days postoperatively (range, 12–121 days), and two patients had died within 30 postoperative days. A comparison between patients with and without POPF indicated significant differences in hospital stay duration (*p* < 0.01).

Comparison of pre-, intra-, and postoperative status between patients with and without POPF

Table 2 summarizes the 17 factors (classified into three categories) compared between patients with and without POPF.

Among preoperative factors, the pancreas-to-muscle SIR on T₁-w MRI was significantly higher in the POPF




Fig. 3 The pancreas-to-muscle signal intensity ratio on fat-suppressed axial T₁-weighted MRI was calculated by [signal intensity of the pancreatic parenchyma] (arrow)/[signal intensity of the paraspinal muscle] (arrowhead)

Table 1 Comparison of clinical outcomes between patients with and without POPF after distal pancreatectomy

	Patients with POPF (n = 29)	Patients without POPF (n = 88)	p-value
Diagnosis days of POPF (day)	7 (3–25)	-	-
Grade of POPF ^a			-
Grade B	27 (93.1)	-	
Grade C	2 (6.9)	-	
Treatment for POPF	•Drain replacement and irrigation	19 (65.5)	-
	•Endoscopic transgastric drainage	7 (24.1)	
	•Antibiotics and octreotide	3 (10.4)	
Postoperative death within 30 days	2 (6.9)	0 (0.0)	0.06
Hospital days (days)	35 (12–121)	13 (7–23)	<0.01 [†]

Data are expressed as median (range) or number of patients (percentage)

POPF Postoperative pancreatic fistula

^a International Study Group (ISGPS) definition and grading of POPF as follows: grade B, symptomatic fistula requiring therapeutic intervention such as antibiotics and percutaneous drainage; grade C, symptomatic fistula associated with a severe general condition of patients, sepsis, and multiorgan failure requiring aggressive treatment in the intensive care unit and surgical intervention

[†] $p < 0.05$

group than in the non-POPF group ($p < 0.01$). Among intraoperative factors, there was no significant difference between the two groups. Among postoperative factors, the D-Amy level on POD 1 and 3 ($p = 0.02$ and $p < 0.01$, respectively), WBC on POD 1 and 3 ($p < 0.01$ and $p = 0.048$, respectively), CRP level on POD 3 ($p < 0.01$), and heart rate on POD 3 ($p < 0.01$) were significantly higher in the POPF group than in the non-POPF group.

Cutoff values of the pancreas-to-muscle SIR on T₁-w MRI and D-Amy levels for predicting POPF

The ROC curves for generating the cutoff values of the pancreas-to-muscle SIR on T₁-w MRI and D-Amy level on POD 1 and 3 are shown in Fig. 4. The cutoff value of the pancreas-to-muscle SIR on T₁-w MRI was +1.37, with an area under the curve (AUC) of 0.741, a sensitivity of 96.3%, and specificity of 52.0% (Fig. 4a). The cutoff value of the D-Amy level on POD 1 was 7238 U/l, with an AUC of 0.729, a sensitivity of 55.2%, and a specificity of 80.5% (Fig. 4b). The cutoff value of the D-Amy level on POD 3 was 737 U/l, with an AUC of 0.721, a sensitivity of 72.4%, and a specificity of 65.5% (Fig. 4c).

Uni- and multivariate analysis of prediction for POPF after DP

In a univariate logistic regression analysis, POPF after DP was significantly associated with the pancreatic-to-muscle SIR on T₁-w MRI ($p < 0.01$), D-Amy level on POD 1 and 3 (both $p < 0.01$), WBC on POD 1 and 3 ($p < 0.01$ and $p = 0.04$, respectively), CRP level on POD 3 ($p < 0.01$), and heart rate on POD 3 ($p = 0.02$).

A multivariate logistic regression analysis revealed that the pancreas-to-muscle SIR on T₁-w MRI (>1.37 ; odds ratio [OR] 23.25; 95% confidence interval [CI] 3.93–454.03; $p < 0.01$) and D-Amy level on POD 3 (>737 U/l; OR 3.91; 95% CI 1.02–16.36; $p = 0.046$), were independent predictive factors of POPF after DP (Table 3).

Discussion

A high incidence of POPF is still reported in pancreatic surgery despite ongoing attempts to reduce its frequency with the development of surgical techniques and devices [4–13]. The clinical nuisance of POPF is that delayed therapeutic intervention can lead to secondary complications [1–3]. This can lead to severe disease and prolonged treatment. In this study, patients with POPF showed an increase in hospital stay duration and mortality. Furthermore, we have previously studied that in PDAC cases, the onset of POPF leads to a delay in initiating postoperative adjuvant chemotherapy [20]. Thus, POPF may affect not only short-term, but also long-term prognosis. Therefore, early and accurate diagnosis of POPF and the promptest possible interventions possible are required. However, this study's median time for POPF diagnosis was 7 days (range, 3–25), making early diagnosis difficult with only routine postoperative examination. We identified two predictive factors for POPF: (i) the pancreas-to-muscle SIR on T₁-w MRI > 1.37 and (ii) the D-Amy level on POD 3 > 737 U/l.

D-Amy levels are among the most established predictive factors for POPF. Therefore, the definition of POPF according to the ISGPF offers the definitive diagnosis according to the D-Amy level on POD 3. In this study, D-Amy levels were also significantly correlated with

Table 2 Comparison of pre-, intra-, and postoperative status between patients with and without POPF after distal pancreatectomy

		Patients with POPF (n=29)	Patients without POPF (n=88)	p-value
Preoperative	Age (years)	67 (40–82)	67 (11–84)	0.87
	Sex			
	Male	18 (62.1)	50 (56.8)	0.67
	Female	11 (37.9)	38 (43.2)	
	BMI (kg/m ²)	23.6 (17.6–32.2)	22.4 (16.2–32.2)	0.37
	Pancreatic ductal adenocarcinoma	12 (41.4)	43 (48.9)	0.53
	Location			
	Body	14 (48.3)	54 (61.4)	0.28
	Tail	15 (51.7)	34 (38.6)	
	Pancreas-to-muscle SIR on T ₁ -w MRI	1.64 (1.25–2.68)	1.35 (0.74–2.16)	<0.01 [†]
Intraoperative	Operative time (min)	284 (174–537)	264 (143–564)	0.13
	Blood loss (ml)	190 (10–1910)	260 (0–1840)	0.84
	Surgical procedure			
	Open	23 (79.3)	60 (68.2)	0.35
	Laparoscopic	6 (20.7)	28 (31.8)	
	Spleen preserving	3 (10.3)	15 (17.1)	0.56
	Non-spleen preserving	26 (89.7)	73 (82.9)	
	Resection procedure			
	Hand-sewn	11 (37.9)	36 (40.9)	0.83
	Stapler	18 (62.1)	52 (59.1)	
	Pancreas texture			
	Soft	21 (72.4)	54 (61.4)	0.37
	Hard	8 (27.6)	34 (38.6)	
	Pancreas thickness (mm)	11 (8–17)	12 (3–24)	0.46
Postoperative	D-Amy levels (U/l)			
	POD 1	7652 (108–34076)	1899 (42–61075)	0.02 [†]
	POD 3	1290 (42–16515)	403 (35–43873)	<0.01 [†]
	WBC (× 10 ³ /μl)			
	POD 1	12.6 (7.5–26.5)	11.1 (5.3–18.2)	<0.01 [†]
	POD 3	13.3 (5.9–26.9)	11.3 (3.9–23.9)	0.048 [†]
	CRP (mg/dl)			
	POD 1	9.3 (1.8–15.4)	8.3 (0.2–17.5)	0.16
	POD 3	20.1 (8.0–33.5)	14.5 (0.3–26.5)	<0.01 [†]
	Body temperature (°C)			
	POD 1	38.0 (37.1–39.4)	38.0 (36.9–39.3)	0.55
	POD 3	37.4 (36.1–38.9)	37.4 (36.2–39.4)	0.30
	Heart rate (bpm)			
	POD 1	98 (81–142)	92 (61–122)	0.07
	POD 3	88 (72–111)	82 (56–119)	<0.01 [†]


Data are expressed as median (range) or number of patients

POPF Postoperative pancreatic fistula, BMI Body mass index, pancreas-to-muscle SIR on T₁-w MRI the pancreas-to-muscle signal intensity ratio on unenhanced T₁-weighted magnetic resonance imaging, D-Amy drainage fluid amylase concentration, POD Postoperative day, WBC White blood cell, CRP C-reactive protein

[†] p < 0.05

POPF. There is no doubt that amylase in the drainage fluid is useful in predicting POPE, as has been reported many times [21–42]. However, the following remain somewhat unclear: (1) the optimal timing of measurement, (2) the

optimal cutoff value, (3) the optimal drain placement site, and (4) whether drainage fluid concentration or the total amount of amylase is more reliable. In addition, postoperative drain obstruction due to fibrin or clots, and drain



misalignment often occurs, interfering with accurate D-Amy level measurements.

The nature of the pancreas itself is thought to play a profound role in the development of POPF. In particular, the texture of pancreatic parenchyma (soft pancreas) has been an important risk factor for POPF. However, the problem is that the pancreatic texture is very subjective and cannot be quantified. To solve this problem, we previously investigated the correlation between preoperative pancreatic MRI features and the histopathological pancreatic fibrosis grade of surgical specimens (fibrosis was graded as follows: F0 = normal pancreatic parenchyma, no fibrotic changes; F1 = mild fibrosis with thickening of periductal fibrosis tissue; F2 = moderate fibrosis with marked sclerosis of interlobular septa and no evidence of architectural changes; and F3 = severe fibrosis with detection of architectural destruction) [16, 17]. We found that the pancreas-to-muscle SIR on T₁-w MRI significantly correlated with

the pancreatic fibrosis grade. This is because normal pancreatic parenchyma exhibits hyperintensity on T₁-w MRI, as pancreatic juice is rich in glycoproteins, and the endoplasmic reticulum within the pancreatic cells contributes to the T₁ shortening effect. However, the signal intensity gradually decreases with the progression of pancreatic atrophy, fibrosis, interstitial edema, or fat deposition [43, 44]. In our previous study, the mean pancreas-to-muscle SIR on T₁-w MRI values for F0 and F1, which correspond to the soft pancreas, were 1.51 and 1.48, respectively. Furthermore, the pancreas-to-muscle SIR on T₁-w MRI in patients with POPF was significantly higher than that in patients without POPF. Based on these findings, we hypothesized that the pancreas-to-muscle SIR on T₁-w MRI might be a potential biomarker for predicting POPF and calculated the cut-off value of 1.41 [16]. Yoon et al. conducted a similar study and reported the mean pancreas-to-muscle SIR on T₁-w MRI values for F0 and F1 and the cutoff value

Table 3 Uni- and multivariate predictive factors of POPF after DP

		n	Univariate			Multivariate		
			OR	95% CI	p-value	OR	95% CI	p-value
Preoperative	Age (years)							
	>70	45	0.79	0.32–1.89	0.61			
	<70	72	1					
	Sex							
	Male	68	1.24	0.53–3.01	0.62			
	Female	49	1					
	BMI (kg/m ²)							
	>24	39	2.07	0.85–5.00	0.10			
	<24	77	1					
	Pancreatic ductal adenocarcinoma							
	Yes	55	0.74	0.31–1.72	0.48			
	No	62	1					
	Location							
	Body	68	0.59	0.25–1.37	0.22			
Tail	49	1						
Pancreas-to-muscle SIR on T ₁ -w MRI	>1.37	61	29.7	5.83–543.73	<0.01 [†]	23.25	3.93–454.03	<0.01 [†]
	<1.37	41	1			1		
Intraoperative	Operative time (min)							
	>300	38	1.36	0.55–3.24	0.50			
	<300	78	1					
	Blood loss (ml)							
	>400	39	0.86	0.33–2.07	0.73			
	<400	77	1					
	Surgical procedure							
	Open	83	1.79	0.69–5.28	0.24			
	Laparoscopic	34	1					
	Spleen preserving	18	0.56	0.12–1.87	0.37			
	Non-spleen preserving	99	1					
	Resection procedure							
	Hand-sewn	47	0.88	0.36–2.07	0.78			
	Stapler	70	1					
Pancreas texture								
Soft	75	1.65	0.68–4.35	0.28				
Hard	42	1						
Pancreas thickness (mm)	>12	56	0.71	0.30–1.64	0.42			
	<12	61	1					

Table 3 (continued)

		n	Univariate			Multivariate		
			OR	95% CI	p-value	OR	95% CI	p-value
Postoperative	D-Amy levels (U/l)—POD 1							
	>7238	33	5.07	2.07–12.78	<0.01 [†]	1.21	0.31–4.75	0.78
	<7238	83	1			1		
	D-Amy levels (U/l)—POD 3							
	>737	51	4.99	2.04–13.25	<0.01 [†]	3.91	1.02–16.36	0.046 [†]
	<737	65	1			1		
	WBC (×10 ³ /μl)—POD 1							
	>1.20	48	3.16	1.34–7.75	<0.01 [†]	2.44	0.69–9.12	0.17
	<1.20	69	1			1		
	WBC (×10 ³ /μl)—POD 3							
	>1.40	34	2.59	1.07–6.29	0.04 [†]	1.03	0.27–3.73	0.96
	<1.40	83	1			1		
	CRP (mg/dl)—POD 1							
	>10	40	1.51	0.63–3.58	0.35			
	<10	77	1					
	CRP (mg/dl)—POD 3							
	>20	34	3.89	1.61–9.60	<0.01 [†]	2.75	0.75–10.70	0.13
	<20	83	1			1		
	Body temperature (°C)—POD 1							
	>38.0	71	0.74	0.32–1.75	0.49			
<38.0	46	1						
Body temperature (°C)—POD 3								
>38.0	14	0.47	0.07–1.87	0.31				
<38.0	103	1						
Heart rate (bpm)—POD 1								
>100	38	2.05	0.85–4.88	0.11				
<100	79	1						
Heart rate (bpm)—POD 3								
>100	13	4.35	1.32–14.81	0.02 [†]	3.84	0.77–21.40	0.10	
<100	104	1			1			

POPF Postoperative pancreatic fistula, OR Odds ratio, 95% CI 95% Confidence interval, BMI Body mass index, pancreas-to-muscle SIR on T₁-w MRI the pancreas-to-muscle signal intensity ratio on unenhanced T₁-weighed magnetic resonance imaging, D-Amy drainage fluid amylase concentration, POD Postoperative day, WBC White blood cell, CRP C-reactive protein

[†] p < 0.05

for predicting POPF was 1.51, 1.48, and 1.40, respectively [45]. Interestingly, the calculated cutoff value for predicting POPF (1.37) in this study is very close to previous studies.

This study had some limitations. First, it was retrospective in design, was undertaken at a single institution, and involved a small number of study patients. The relatively small sample size may have caused a selection bias and

multiplicity issues in statistical analysis. This limitation should be considered when evaluating our study results. A prospective, multi-centered study is needed involving a larger number of patients in the future. Second, there were the technical variations in the surgical procedure of DP, such as open or laparoscopic, spleen preserving or non-preserving, hand-sewn or stapler, and lymph node dissection or not. This study found no significant correlation between surgical-related factors and POPF. It is necessary to unify surgical techniques in order to calculate more appropriate cutoff values of the pancreas-to-muscle SIR on T₁-weighted MRI and D-Amy levels.

Conclusions

We found that the pancreas-to-muscle SIR on T₁-weighted MRI and D-Amy levels may have predictive value for POPF. The pancreas-to-muscle SIR is an objective and quantitative biomarker reflecting pancreatic characteristics. Postoperative management based on the pancreas-to-muscle SIR on T₁-weighted MRI may contribute to a shortened hospital stay.

Abbreviations

BMI: Body mass index; CI: Confidence interval; CT: Computed tomography; D-Amy: Drainage fluid amylase; DP: Distal pancreatectomy; MRI: Magnetic resonance imaging; OR: Odds ratio; ISGPF: International Study Group of Pancreatic Fistula; PD: Pancreaticoduodenectomy; PDAC: Pancreatic ductal adenocarcinoma; POD: Postoperative day; POPF: Postoperative pancreatic fistula; ROC: Receiver operating characteristic; SIR on T₁-w MRI: Signal intensity ratio on T₁-weighted MRI; US: Ultrasonography.

Acknowledgements

The authors thank the medical staff of the Department of Gastroenterological Surgery at Gifu University Hospital for their participation in this study. We could not have completed this study without their diligence and support. We would also like to thank Editage (www.editage.jp) for the English language editing.

Authors' contributions

MF conceived the study concept and planned the design as the principal investigator. MF interpreted the results and wrote the manuscript draft. KM and TH revised the manuscript draft through adding intellectual content and providing critical advice. MF, KM, TH, SF, MK, IY, YS, SK, YT, NO, NM, and TT obtained the data and provided critical comments to improve the manuscript and gave final approval for submission. The author(s) read and approved the final manuscript.

Funding

Not applicable.

Availability of data and materials

The datasets used during this study are available from the corresponding author upon reasonable request.

Declarations

Ethics approval and consent to participate

The present study was conducted in accordance with the World Medical Association Declaration of Helsinki and was approved by the Ethics Committee of Gifu University (approval number "2021-26"). As this study was a retrospective study and did not include any potentially identifiable patient data, informed consent was not obtained from the enrolled patients. Our Institutional Review Board approved this retrospective study.

Consent for publication

Not applicable.

Competing interests

T. Takahashi received honoraria for lectures from Takeda Pharmaceutical Co., Ltd. The remaining authors declare that they have no competing interests.

Received: 17 May 2022 Accepted: 26 July 2022

Published online: 05 August 2022

References

- Fujino Y. Perioperative management of distal pancreatectomy. *World J Gastroenterol.* 2015;21:3166–9. <https://doi.org/10.3748/wjg.v21.i11.3166> PMID: 25805921.
- Sell NM, Pucci MJ, Gabale S, Leiby BE, Rosato EL, Winter JM, et al. The influence of transection site on the development of pancreatic fistula in patients undergoing distal pancreatectomy: a review of 294 consecutive cases. *Surgery.* 2015;157:1080–7. <https://doi.org/10.1016/j.surg.2015.01.014> Epub 2015 Mar 16. PMID: 25791028.
- Glowka TR, von Websky M, Pantelis D, Manekeller S, Standop J, Kalff JC, et al. Risk factors for delayed gastric emptying following distal pancreatectomy. *Langenbecks Arch Surg.* 2016;401:161–7. <https://doi.org/10.1007/s00423-016-1374-7> Epub 2016 Jan 27. PMID: 26814716.
- Andrianello S, Marchegiani G, Malleo G, Masini G, Balduzzi A, Paiella S, et al. Pancreaticojejunostomy with externalized stent vs pancreaticogastrostomy with externalized stent for patients with high-risk pancreatic anastomosis: a single-center, phase 3, randomized clinical trial. *JAMA Surg.* 2020;155:313–21. <https://doi.org/10.1001/jamasurg.2019.6035>.
- Zhang H, Zhu F, Shen M, Tian R, Shi CJ, Wang X, et al. Systematic review and meta-analysis comparing three techniques for pancreatic remnant closure following distal pancreatectomy. *Br J Surg.* 2015;102:4–15. <https://doi.org/10.1002/bjs.9653>.
- Kawai M, Tani M, Terasawa H, Ina S, Hirono S, Nishioka R, et al. Early removal of prophylactic drains reduces the risk of intra-abdominal infections in patients with pancreatic head resection: prospective study for 104 consecutive patients. *Ann Surg.* 2006;244:1–7. <https://doi.org/10.1097/01.sla.0000218077.14035.a6>.
- Xiong JJ, Tan CL, Szatmary P, Huang W, Ke NW, Hu WM, et al. Meta-analysis of pancreaticogastrostomy versus pancreaticojejunostomy after pancreaticoduodenectomy. *Br J Surg.* 2014;101:1196–208. <https://doi.org/10.1002/bjs.9553>.
- Hirano S, Kondo S, Hara T, Ambo Y, Tanaka E, Shichinohe T, et al. Distal pancreatectomy with en bloc celiac axis resection for locally advanced pancreatic body cancer: long-term results. *Ann Surg.* 2007;246:46–51. <https://doi.org/10.1097/01.sla.0000258608.52615.5a> PMID: 17592290.
- McPhee JT, Hill JS, Whalen GF, Zayazuzny M, Litwin DE, Sullivan ME, et al. Perioperative mortality for pancreatectomy: a national perspective. *Ann Surg.* 2007;246:246–53. <https://doi.org/10.1097/01.sla.0000259993.17350.3a> PMID: 17667503.
- Sledzianowski JF, Duffas JP, Muscari F, Suc B, Fourtanier F. Risk factors for mortality and intra-abdominal morbidity after distal pancreatectomy. *Surgery.* 2005;137:180–5. <https://doi.org/10.1016/j.surg.2004.06.063> PMID: 15674199.
- Goh BK, Tan YM, Chung YF, Cheow PC, Ong HS, Chan WH, et al. Critical appraisal of 232 consecutive distal pancreatectomies with emphasis on risk factors, outcome, and management of the postoperative pancreatic fistula: a 21-year experience at a single institution. *Arch Surg.* 2008;143:956–65. <https://doi.org/10.1001/archsurg.143.10.956> PMID: 18936374.
- Shimada K, Sakamoto Y, Sano T, Kosuge T. Prognostic factors after distal pancreatectomy with extended lymphadenectomy for invasive pancreatic adenocarcinoma of the body and tail. *Surgery.* 2006;139:288–95. <https://doi.org/10.1016/j.surg.2005.08.004> PMID: 16546491.
- Lillemoe KD, Kaushal S, Cameron JL, Sohn TA, Pitt HA, Yeo CJ. Distal pancreatectomy: indications and outcomes in 235 patients. *Ann Surg.* 1999;229:693–8. <https://doi.org/10.1097/0000658-199905000-00012> discussion 698–700. PMID: 10235528.
- Hashimoto Y, Sclabas GM, Takahashi N, Kirihara Y, Smyrk TC, Huebner M, et al. Dual-phase computed tomography for assessment of pancreatic fibrosis and anastomotic failure risk following pancreaticoduodenectomy.

- J Gastrointest Surg. 2011;15:2193–204. <https://doi.org/10.1007/s11605-011-1687-3>.
15. Kim Z, Kim MJ, Kim JH, Jin SY, Kim YB, Seo D, et al. Prediction of postoperative pancreatic fistula in pancreaticoduodenectomy patients using preoperative MRI: a pilot study. *HPB (Oxford)*. 2009;11:215–21. <https://doi.org/10.1111/j.1477-2574.2009.00011.x>.
 16. Watanabe H, Kanematsu M, Tanaka K, Osada S, Tomita H, Hara A, et al. Fibrosis and postoperative fistula of the pancreas: correlation with MR imaging findings—preliminary results. *Radiology*. 2014;270:791–9. <https://doi.org/10.1148/radiol.13131194> Epub 2013 Nov 8. PMID: 24475834.
 17. Noda Y, Goshima S, Suzui N, Miyazaki T, Kajita K, Kawada H, et al. Pancreatic MRI associated with pancreatic fibrosis and postoperative fistula: comparison between pancreatic cancer and non-pancreatic cancer tissue. *Clin Radiol*. 2019;74:490.e1–6. <https://doi.org/10.1016/j.crad.2019.02.013> Epub 2019 Mar 23. PMID: 30914207.
 18. Japan Pancreas Society. Classification of pancreatic carcinoma. 4th ed. Tokyo: Kanehara & Co., Ltd.; 2017.
 19. Bassi C, Dervenis C, Butturini G, Fingerhut A, Yeo C, Izbicki J, et al. Postoperative pancreatic fistula: an international study group (ISGPF) definition. *Surgery*. 2005;138:8–13. <https://doi.org/10.1016/j.surg.2005.05.001> PMID: 16003309.
 20. Fukada M, Murase K, Higashi T, Yokoi R, Tanaka Y, Okumura N, et al. Early predictive factors for postoperative pancreatic fistula after distal pancreatectomy for pancreatic cancer. *Cancer Diagn Progn*. 2022;2:452–61. <https://doi.org/10.21873/cdp.10128> PMID: 35813012.
 21. Ridolfini MP, Alfieri S, Gourgoutis S, Di Miceli D, Rotondi F, Quero G, et al. Risk factors associated with pancreatic fistula after distal pancreatectomy, which technique of pancreatic stump closure is more beneficial? *World J Gastroenterol*. 2007;13:5096–100. <https://doi.org/10.3748/wjg.v13.i38.5096> PMID: 17876875.
 22. Pannegeon V, Pessaux P, Sauvanet A, Vullierme MP, Kianmanesh R, Belghiti J. Pancreatic fistula after distal pancreatectomy: predictive risk factors and value of conservative treatment. *Arch Surg*. 2006;141:1071–6. <https://doi.org/10.1001/archsurg.141.11.1071> Discussion 1076. PMID: 17116799.
 23. Yoshioka R, Saiura A, Koga R, Seki M, Kishi Y, Morimura R, et al. Risk factors for clinical pancreatic fistula after distal pancreatectomy: analysis of consecutive 100 patients. *World J Surg*. 2010;34:121–5. <https://doi.org/10.1007/s00268-009-0300-3> PMID: 20020297.
 24. Distler M, Kersting S, Rückert F, Kross P, Saeger HD, Weitz J, et al. Chronic pancreatitis of the pancreatic remnant is an independent risk factor for pancreatic fistula after distal pancreatectomy. *BMC Surg*. 2014;14:54. <https://doi.org/10.1186/1471-2482-14-54> PMID: 25127883.
 25. Gomes RM, Doctor N. Three level risk assessment for pancreatic fistula formation after distal pancreatectomy with a strategy for prevention. *Trop Gastroenterol*. 2012;33:207–13. <https://doi.org/10.7869/tg.2012.50> PMID: 23600052.
 26. Soga K, Ochiai T, Sonoyama T, Inoue K, Ikoma H, Kikuchi S, et al. Risk factors for postoperative pancreatic fistula in distal pancreatectomy. *Hepato-Gastroenterology*. 2011;58:1372–6. <https://doi.org/10.5754/hge09255> PMID: 21937410.
 27. Kawabata Y, Nishi T, Tanaka T, Yano S, Tajima Y. Distal pancreatectomy utilizing a flexible stapler closure eliminates the risk of pancreas-related factors for postoperative pancreatic fistula. *Eur Surg Res*. 2013;50:71–9. <https://doi.org/10.1159/000349977> Epub 2013 Apr 23. PMID: 23614941.
 28. Eguchi H, Nagano H, Tanemura M, Takeda Y, Marubashi S, Kobayashi S, et al. A thick pancreas is a risk factor for pancreatic fistula after a distal pancreatectomy: selection of the closure technique according to the thickness. *Dig Surg*. 2011;28:50–6. <https://doi.org/10.1159/000322406> Epub 2011 Feb 4. PMID: 21293132.
 29. Sugimoto M, Gotohda N, Kato Y, Takahashi S, Kinoshita T, Shibasaki H, et al. Risk factor analysis and prevention of postoperative pancreatic fistula after distal pancreatectomy with stapler use. *J Hepato-Bil Pancreat Sci*. 2013;20:538–44. <https://doi.org/10.1007/s00534-013-0596-0> PMID: 23430057.
 30. Kah Heng CA, Salleh I, San TS, Ying F, Su-Ming T. Pancreatic fistula after distal pancreatectomy: incidence, risk factors and management. *ANZ J Surg*. 2010;80:619–23. <https://doi.org/10.1111/j.1445-2197.2010.05337.x> PMID: 20840405.
 31. Makni A, Rebai W, Daghfouss A, Ayadi S, Fterich F, Chebbi F, et al. Risk factors associated with pancreatic fistula after distal pancreatectomy. *Tunis Med*. 2012;90:148–53 PMID: 22407627.
 32. Sierzega M, Niekowal B, Kulig J, Popiela T. Nutritional status affects the rate of pancreatic fistula after distal pancreatectomy: a multivariate analysis of 132 patients. *J Am Coll Surg*. 2007;205:52–9. <https://doi.org/10.1016/j.jamcollsurg.2007.02.077> PMID: 17617332.
 33. Kawai M, Tani M, Yamaue H. Transection using bipolar scissors reduces pancreatic fistula after distal pancreatectomy. *J Hepato-Bil Pancreat Surg*. 2008;15:366–72. <https://doi.org/10.1007/s00534-008-1330-1> Epub 2008 Aug 1. PMID: 18670836.
 34. Sato N, Mori Y, Minagawa N, Tamura T, Shibao K, Higure A, et al. Rapid postoperative reduction in prognostic nutrition index is associated with the development of pancreatic fistula following distal pancreatectomy. *Pancreateology*. 2014;14:216–20. <https://doi.org/10.1016/j.pan.2014.02.006> Epub 2014 Mar 18. PMID: 24854618.
 35. Subhedar PD, Patel SH, Kneuert PJ, Maithe SK, Staley CA, Sarmiento JM, et al. Risk factors for pancreatic fistula after stapled gland transection. *Am Surg*. 2011;77:965–70. <https://doi.org/10.1177/000313481107700811> PMID: 21944507.
 36. Mendoza AS 3rd, Han HS, Ahn S, Yoon YS, Cho JY, Choi Y. Predictive factors associated with postoperative pancreatic fistula after laparoscopic distal pancreatectomy: a 10-year single-institution experience. *Surg Endosc*. 2016;30:649–56. <https://doi.org/10.1007/s00464-015-4255-1> Epub 2015 Jun 20. PMID: 26091993.
 37. Okano K, Oshima M, Kakinoki K, Yamamoto N, Akamoto S, Yachida S, et al. Pancreatic thickness as a predictive factor for postoperative pancreatic fistula after distal pancreatectomy using an endopath stapler. *Surg Today*. 2013;43:141–7. <https://doi.org/10.1007/s00595-012-0235-4> Epub 2012 Jul 11. PMID: 22782593.
 38. Frozanpor F, Albiin N, Linder S, Segersvärd R, Lundell L, Arnelo U. Impact of pancreatic gland volume on fistula formation after pancreatic tail resection. *JOP*. 2010;11:439–43 PMID: 20818111.
 39. Noji T, Nakamura T, Ambo Y, Suzuki O, Nakamura F, Kishida A, et al. Clinically relevant pancreas-related infectious complication after pancreatico-coentral anastomosis could be predicted by the parameters obtained on postoperative day 3. *Pancreas*. 2012;41:916–21. <https://doi.org/10.1097/MPA.0b013e31823e7705> PMID: 22481291.
 40. Kanda M, Fujii T, Takami H, Suenaga M, Inokawa Y, Yamada S, et al. Novel diagnostics for aggravating pancreatic fistulas at the acute phase after pancreatectomy. *World J Gastroenterol*. 2014;20:8535–44. <https://doi.org/10.3748/wjg.v20.i26.8535> PMID: 25024608.
 41. Fukami Y, Saito T, Osawa T, Hanazawa T, Kurahashi T, Kurahashi S, et al. Which is the best predictor of clinically relevant pancreatic fistula after pancreatectomy: drain fluid concentration or total amount of amylase? *Ann Gastroenterol Surg*. 2021;5:844–52. <https://doi.org/10.1002/ags3.12471> PMID: 34755016.
 42. Matar A, Meares T, Fisher OM, Gauci C, Rao A, Alshahrani M, et al. Postoperative pancreatic fistula after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: an update on incidence, risk factors, management, and clinical sequelae in 1,141 patients. *Anticancer Res*. 2021;41:5577–84. <https://doi.org/10.21873/anticancer.15371> PMID: 34732428.
 43. Mitchell DG, Vinitski S, Saponaro S, Tasciyan T, Burk DL Jr, Rifkin MD. Liver and pancreas: improved spin-echo T1 contrast by shorter echo time and fat suppression at 1.5 T. *Radiology*. 1991;178:67–71. <https://doi.org/10.1148/radiology.178.1.1984328> PMID: 1984328.
 44. Winston CB, Mitchell DG, Outwater EK, Ehrlich SM. Pancreatic signal intensity on T1-weighted fat saturation MR images: clinical correlation. *J Magn Reson Imaging*. 1995;5:267–71. <https://doi.org/10.1002/jmri.1880050307> PMID: 7633102.
 45. Yoon JH, Lee JM, Lee KB, Kim SW, Kang MJ, Jang JY, et al. Pancreatic steatosis and fibrosis: quantitative assessment with preoperative multiparametric MR imaging. *Radiology*. 2016;279:140–50. <https://doi.org/10.1148/radiol.2015142254>.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.